AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06180018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interrupted sutures
Description: Using interrupted sutures in repair of hypospadias by Snodgrass TIP repair
Study NCT06155526 — intervention group
Intervention type: OTHER
Intervention: Activity
Description: patients taking an active rest after swimming sets
Study NCT06334432 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NUV-1511
Description: Novel small molecule
Study NCT06334432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-1511
Description: Novel small molecule
Study NCT05516992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-01 For Injection
Description: Intradiscal injection
Study NCT05516992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham Needle
Description: Sham needle placement
Study NCT05064735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide 2.4 mg
Description: semaglutide subcutaneous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
Study NCT05064735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: semaglutide 2.4 mg (placebo)
Description: semaglutide subcutanous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
Study NCT06561919 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper
Description: Best medical treatment according to widely accepted expert consensus Paper
Study NCT06561919 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper
Description: Best medical treatment according to widely accepted consensus Paper
Study NCT04727970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin will be emulsified in infant formula/milk
Study NCT05226442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Argatroban is a synthetic, univalent DTI, that directly binds to the catalytic thrombin binding site exerting its effects
Study NCT05226442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Unfractionated heparin produces its major anticoagulant effect by inactivating thrombin and activated factor X (factor Xa) through an antithrombin (AT)-dependent mechanism.
Study NCT05895786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06823859
Description: anti-interferon beta therapy
Study NCT05895786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06823859
Study NCT06194825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplontersen
Description: Eplontersen by subcutaneous injection
Study NCT06194825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eplontersen-matching placebo by subcutaneous injection
Study NCT05650749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GPC2 CAR T cells
Description: The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimeric antigen receptor (CAR) transgene.
Study NCT05890664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide.~Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether.
Study NCT05890664 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.
Study NCT06585657 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain visual perception training group
Description: Conduct brain visual perception training through a visual training system to improve binocular visual balance. Train 2 projects per day, each lasting 10 minutes.
Study NCT05387278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV-Pure™ and WJ-Pure™
Description: The treatment consists of administration of WJ-Pure™ and EV-Pure™ plus standard care
Study NCT05387278 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cryopreservation media plus standard care
Study NCT05462145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Globe Pulsed Field System
Description: Ablation and atrial mapping with the Globe Pulsed Field System
Study NCT06459674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrO2 Fit (IMT Trainer)
Description: The device is used four times a week over a period of 8 weeks.
Study NCT06459674 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PrO2 Fit (IMT Trainer)
Description: The device is used four times a week over a period of 8 weeks.
Study NCT06340581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: BGF MDI HFA
Description: Participants will receive 4 oral inhalations of BGF MDI HFA as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
Study NCT06340581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: BGF MDI HFO
Description: Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose with AeroChamber Plus Flow-Vu spacer with charcoal.
Study NCT06340581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C: BGF MDI HFO
Description: Participants will receive 4 oral inhalations of BGF MDI HFO as a single dose without spacer with charcoal.
Study NCT06340581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroChamber Plus Flow-Vu Spacer
Description: Participants will receive 4 inhalations of BGF MDI HFA (treatment A) and BGF MDI HFO (Treatment B) as a single dose with AeroChamber Plus Flow-Vu spacer.
Study NCT04825574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablet
Study NCT03255408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep
Description: The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
Study NCT03255408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Lowering CBF and Intermittent Hypoxia Sleep
Description: The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
Study NCT03255408 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo and Normoxia Sleep
Description: The study participants will take Placebo and sleep under Normoxia Exposure
Study NCT03255408 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Intermittent Hypoxia Sleep
Description: The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
Study NCT06477055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib, 80mg, po, qd.
Study NCT06652243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SN301A
Description: SN301A is an investigational off-the-shelf CAR NK cell therapy, armed with calibrated release (cr)IL15, designed to selectively target and treat GPC3 expressing advanced hepatocellular carcinoma.~Subjects will receive lymphodepletion pretreatment (Fludarabine/Cyclophosphamide), three SN301A intravenous infusions in a cycle (D0, D7, D14), with each subject receiving a maximum of 3 cycles.
Study NCT05653492 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane
Description: Dosing study one to four 30 mg/d tablets depending on weight
Study NCT06596369 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Continuous, sub motor threshold stimulation is delivered through surface electrodes placed over the cervical spine region.
Study NCT06596369 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity rehabilitation
Description: Using the ReJoyce system individuals will engage in upper extremity rehabilitation.
Study NCT06598046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone and capecitabine
Description: Utidelone: intravenous capecitabine: oral
Study NCT06590922 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group using new oropharyngeal airway (experimental group)
Description: Before anesthesia induction, study participants in the experimental group received 5-6L/min oxygen for about 1min through an endoscopic bite oxygen supply device, and anesthesia induction was administered with propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. When participants achieved sufficient sedation (about BIS40), they were placed into the oropharyngeal airway through the endoscopic bite and began gastroscopy.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
Study NCT06590922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The conventional endoscopic biting group (control group)
Description: Prior to induction of anesthesia, control study participants inhaled 5 to 6L/min of oxygen through a nasal catheter for approximately 1 minute.Anesthesia was induced by propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. The endoscopic procedure began when the study participants reached sufficient sedation (about BIS40) and the ordinary endoscopic bite group reached sufficient sedation.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.
Study NCT06589284 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Silk 0-0 suture covered by chlorhexidine gluconate dressing
Description: The specific intervention will be securing radial arterial catheters with either skin adhesive or suture material. Both are largely accepted to be standard of care but to date there is a paucity of literature directly comparing the two for radial arterial lines. During the intervention the placement of radial arterial catheters will be done via standard sterile procedure and using seldinger technique which involves using a guidewire to slide the arterial catheter into the radial artery. After the catheter is placed, it will be secure with either straight suture with a cutting needle or via skin adhesive. Following securement, the area will be cleaned and a Tegaderm dressing with biopatch will be placed over the catheter. Data will be collected immediately after the procedure including length of procedure and complications as well as via chart review to determine the length of time the catheter was in place and evidence of premature failure.
Study NCT06589284 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 2-octyl cyanoacrylate covered by chlorhexidine gluconate dressing
Description: The specific intervention will be securing radial arterial catheters with either skin adhesive or suture material. Both are largely accepted to be standard of care but to date there is a paucity of literature directly comparing the two for radial arterial lines. During the intervention the placement of radial arterial catheters will be done via standard sterile procedure and using seldinger technique which involves using a guidewire to slide the arterial catheter into the radial artery. After the catheter is placed, it will be secure with either straight suture with a cutting needle or via skin adhesive. Following securement, the area will be cleaned and a Tegaderm dressing with biopatch will be placed over the catheter. Data will be collected immediately after the procedure including length of procedure and complications as well as via chart review to determine the length of time the catheter was in place and evidence of premature failure.
Study NCT06602986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TACE
Description: study was carried out in our setup for two major reasons. One was to decrease reliance on DSA since it is a costly investigation in our medical setups and the facility is not available except for a few centers of excellence which creates issues with treatments plan of patients admitted for treatment using TACE and subsequent follow-up visits to assess the presence or absence of HCC tumors. The mean age of patients in our treatment group was in the early sixties. This is in line with the median age of diagnosis for HCC globally as evidenced by studies done by Mc Glynn et al12 and Konyn et al13. Gender distribution was predominantly male in our study group in line with available literature14. The Child Pugh classification which quantifies severity of chronic liver disease by assessing clinical parameters was used in our study as well15. Since the inclusion criteria and procedural requirement required normal bilirubin levels, all subjects in the study protocol were in Class A16.~The prima
Study NCT06603506 — intervention group
Intervention type: OTHER
Intervention: tumour and blood samples
Description: Tumour and blood samples
Study NCT05006352 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL343
Description: Oral repeating dose
Study NCT05006352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral repeating dose
Study NCT06591390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor 90 MG
Description: The ticagrelor arm will receive (a 180mg loading dose of cilostazol during the first 24 hours of stroke onset, followed by 90mg once daily from the 2nd day to the 90th day) and an open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin
Study NCT06591390 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 MG
Description: The cilostazol arm will receive (a 200 mg loading dose of clopidogrel during the first 24 hours of stroke onset, followed by 100 mg twice daily from the 2nd day to the 90th day) and open-label loading 300 mg aspirin, followed by a maintenance dose of 75 mg aspirin.
Study NCT06591507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA Nutritional Intervention
Description: Patients will receive BCAA nutritional supplements. The supplement is taken orally twice daily, with each sachet containing 10g of powder, of which 6g is BCAA, and the remainder consists of preservatives and fruit flavorings to enhance palatability. The morning dose is taken with breakfast, and the second dose is taken as a late evening snack after dinner. For critically ill patients, enteral nutrition is provided instead. During each follow-up visit, patients are required to retain and submit all empty and unused sachets to accurately assess compliance. Dietitians will adjust the type and amount of food for each patient according to the guidelines of the European Society for Parenteral and Enteral Nutrition to ensure a total caloric intake of 35-40 kcal/kg and a protein intake of 1.2-1.5 g/kg (including BCAA supplements).
Study NCT06591507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Rehabilitation Training
Description: Phase 1: Resistance Training (During Hospital Stay, First Month) Phase 2: Resistance Training (Home-Based, From Hospital Discharge Until 3 Months Post-Surgery) Phase 3: Physical Activity Training (Post-Surgery, After 3 Months)
Study NCT06591507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard Nutritional Therapy
Description: Standard Nutritional Therapy
Study NCT06594120 — intervention group
Intervention type: BEHAVIORAL
Intervention: Multimodal rehabilitation with additional work specific training
Description: The rehabilitation is based on the biopsychosocial ICF model of the WHO. Taking into account the physical and psychological condition of the patients, an individual therapy plan is created that is tailored to the needs of the patients.
Study NCT06596863 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The association of serum uromodulin with DN
Description: Meta analysis of association of serum uromodulin with DKD
Study NCT06596863 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN
Description: DN patients were divided according to the level of albumin to creatinine ratio (ACR), glomerular filtration rate (GFR), or albumin excretion rate (AER) in patients with DN
Study NCT06588335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTLA inhibitor (JS004)
Description: BTLA inhibitor (JS004):200mg, intravenous infusion , d1, Q3W;
Study NCT06588335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab:240mg,intravenous infusion, d1, Q3W;
Study NCT06588335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin
Description: Paclitaxel, 175mg/m2, intravenous infusion, d1, Q3W; Cisplatin, 75mg/m2, intravenous infusion, d1, Q3W;
Study NCT05163158 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Central vs brachial systolic blood pressure targeting
Description: Participants will be randomized to either a central BP target (intervention) or a brachial BP target (standard care). For each group, the source of the BP (central or brachial) will be blinded and only the BP values will be provided to the attending Nephrologist. In both cases, the target SBP will be \<130 mmHg.
Study NCT05163158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Central vs brachial systolic blood pressure targeting
Description: Participants will be randomized to either a central BP target (intervention) or a brachial BP target (standard care). For each group, the source of the BP (central or brachial) will be blinded and only the BP values will be provided to the attending Nephrologist. In both cases, the target SBP will be \<130 mmHg.
Study NCT06601452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a compound prescription of Chinese medicine
Description: The enrolled patients were treated with 3 cycles of sequential treatment with Nourishing Yin and Replenishing Yang formula before entering the cycle (Tuning Weekly Nourishing Yin Granules + Tuning Weekly Replenishing Yang Granules), and the egg retrieval cycle used an antagonist regimen to obtain the eggs.
Study NCT06595173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Intervention
Description: group where therapeutic art activities such as mandala, drawing, third person singular method are applied.~Therapeutic artistic activities within the program (drawing, zentagle, etc.). The program will be implemented in 6 weeks. At the beginning and end of the program, children\&#39;s anxiety and psychological well-being levels will be evaluated.
Study NCT06538480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRGN-2012
Description: PRGN-2012 will be administered as 4 subcutaneous administrations over a 12-week interval.
Study NCT06538896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + Nab-Paclitaxel
Description: Tislelizumab, 200mg, intravenous, every 3 weeks
Study NCT06538896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rankl inhibitor
Description: RANKL inhibitor determined by investigator is administered at a dose of 120 mg every 4 weeks, with dosing on Days 1, 8, and 15 during the first cycle.
Study NCT04752618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: P-STAIR
Description: PCIT+ STAIR
Study NCT04752618 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Counseling
Description: Non-trauma focused psychotherapy
Study NCT05472090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study NCT05472090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SL Tablet
Description: Patients will take 1 tablet of randomly assigned study drug sublingually starting on Day 1 for 2 weeks. At the Week 2 visit, all patients will have the dose increased to 2 tablets for 12 weeks.
Study NCT04093297 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tricuspid Annuloplasty
Description: Patients will undergo repair of tricuspid regurgitation
Study NCT06599489 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery ..operation
Description: sleeve gastrectomy with cruroplasty with or without ligamentum teres wrapping
Study NCT06705127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION(JS001 )
Description: Drug A: 240mg intravenous infusion of Toripalimab, once every 3 weeks, the first dosing date was C1D1, followed by the first day of each course for 18 cycles, a total of 1 year.~Drugs B and C: Epirubicin was administered intravenously after the dosage was calculated at 90mg/m2 body surface area, cyclophosphamide was calculated at 600mg/m2 body surface area by intravenous micropump, both drugs were administered every 3 weeks, the first administration date was C1D1, and then the first day of each course was administered for 4 cycles.~Drug D:albumin paclitaxel was given intravenatically at a dose of 125mg/m2 body surface area, once a week, with the first administration date of C5D1, and then on the first day of each course for 12 cycles.